BeyondSpring Inc. reported its second-quarter 2025 financial results on August 13, 2025, showing an improved net loss from continuing operations of $1.88 million, down from $2.65 million in Q2 2024. For the six months ended June 30, 2025, the net loss from continuing operations was $4.46 million, an improvement from $4.73 million in the prior-year period. Research and development expenses increased to $1.88 million for the six months, while general and administrative expenses decreased to $2.68 million.
The company also provided an update on its liquidity, stating that as of June 30, 2025, continuing operations held $9.50 million in cash and cash equivalents. The first closing of the SEED Therapeutics divestiture in February 2025 generated approximately $7.35 million in cash, contributing to $17.20 million in net cash from investing activities for the six months. This transaction also resulted in a $6.99 million gain on the sale of subsidiary interests.
BeyondSpring anticipates receiving an additional $28.07 million from subsequent tranches of the SEED divestiture, with closings expected by December 15, 2025, and December 15, 2026. Management projects that current financial resources, supplemented by these expected proceeds, will be sufficient to cover operational expenses and capital expenditures for the next 12 months. Additionally, SEED Therapeutics' RBM39 degrader ST-01156 cleared FDA IND and is advancing toward Phase 1 trials.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.